News | April 30, 2026
RPG Life Sciences reports Rs 707.5 crore revenue in FY26, 8% annual growth
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
The agreements aim to strengthen medicine quality, patient safety and pharmaceutical research in India
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Platform integrates VR simulations and AI-driven coaching to build job-ready skills in pharma manufacturing
CLIRNET plans to expand globally and improve how medical knowledge is shared and used in practice
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
Subscribe To Our Newsletter & Stay Updated
